Subscribe Login
Jamaica Observer
ePaper
The Edge 105 FM Radio Fyah 105 FM
Jamaica Observer
ePaper
The Edge 105 FM Radio Fyah 105 FM
    • Home
    • News
      • Latest News
      • Cartoon
      • International News
      • Central
      • North & East
      • Western
      • Environment
      • Health
      • #
    • Business
      • Business Bites
      • Social Love
    • Sports
      • Football
      • Basketball
      • Cricket
      • Horse Racing
      • World Champs
      • Commonwealth Games
      • FIFA World Cup
      • Olympics
      • #
    • Videos
    • Entertainment
      • Music
      • Movies
      • Art & Culture
      • Bookends
      • #
    • Lifestyle
      • Page2
      • Food
      • Tuesday Style
      • Food Awards
      • JOL Takes Style Out
      • Design Week JA
      • Black Friday
      • #
    • All Woman
      • Home
      • Relationships
      • Features
      • Fashion
      • Fitness
      • Rights
      • Parenting
      • Advice
      • #
    • Obits
    • Classifieds
      • Employment
      • Property
      • Motor Vehicles
      • Place an Ad
      • Obituaries
    • More
      • Games
      • Elections
      • Jobs & Careers
      • Study Centre
      • Jnr Study Centre
      • Letters
      • Columns
      • Advertorial
      • Editorial
      • Supplements
      • Webinars
    • Home
    • News
      • Latest News
      • Cartoon
      • International News
      • Central
      • North & East
      • Western
      • Environment
      • Health
      • #
    • Business
      • Business Bites
      • Social Love
    • Sports
      • Football
      • Basketball
      • Cricket
      • Horse Racing
      • World Champs
      • Commonwealth Games
      • FIFA World Cup
      • Olympics
      • #
    • Videos
    • Entertainment
      • Music
      • Movies
      • Art & Culture
      • Bookends
      • #
    • Lifestyle
      • Page2
      • Food
      • Tuesday Style
      • Food Awards
      • JOL Takes Style Out
      • Design Week JA
      • Black Friday
      • #
    • All Woman
      • Home
      • Relationships
      • Features
      • Fashion
      • Fitness
      • Rights
      • Parenting
      • Advice
      • #
    • Obits
    • Classifieds
      • Employment
      • Property
      • Motor Vehicles
      • Place an Ad
      • Obituaries
    • More
      • Games
      • Elections
      • Jobs & Careers
      • Study Centre
      • Jnr Study Centre
      • Letters
      • Columns
      • Advertorial
      • Editorial
      • Supplements
      • Webinars
  • Home
  • News
    • International News
  • Latest
  • Business
    • Business Bites
  • Cartoon
  • Games
  • Food Awards
  • Health
  • Entertainment
    • Bookends
  • Regional
  • Sports
    • Sports
    • World Cup
    • World Champs
    • Olympics
  • Videos
  • Career & Education
  • Classifieds
  • All Woman
  • Environment
  • Webinars
  • More
    • Football
    • Elections
    • Letters
    • Advertorial
    • Columns
    • Editorial
    • Supplements
  • Epaper
  • Design Week
Drug slows Alzheimer’s but can it make a real difference?
Scientists don't yet know exactly how Alzheimer's forms but one theory is that gunky amyloid build-up plays a key role, although drug after drug that targets it has failed. (Photo: Pixabay)
News
December 18, 2022

Drug slows Alzheimer’s but can it make a real difference?

SAN FRANCISCO, United States (AP) — An experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening — but the anxiously awaited new data leaves unclear how much difference that might make in people’s lives.

Japanese drugmaker Eisai and its US partner Biogen had announced earlier this fall that the drug lecanemab appeared to work, a badly needed bright spot after repeated disappointments in the quest for better treatments of the incurable disease.

The companies recently provided full results of the study of nearly 1,800 people in early stages of the mind-robbing disease. The data was presented at an Alzheimer’s meeting in San Francisco and published in The New England Journal of Medicine.

Lecanemab delayed patients’ worsening by about five months over the course of the 18-month study, Eisai’s Dr Michael Irizarry told The Associated Press. Also, lecanemab recipients were 31 per cent less likely to advance to the next stage of the disease during the study.

“That translates to more time in earlier stages” when people function better, Irizarry said.

Every two weeks, study participants received intravenous lecanemab or a dummy infusion. Researchers tracked them using an 18-point scale that measures cognitive and functional ability.

The study’s key finding: Those given lecanemab declined more slowly, a difference of not quite half a point on that scale over the 18 months, concluded the research team led by Dr Christopher van Dyck at Yale University.

Doctors are divided over how much difference that may make for patients and families — especially as the drug carries some worrying potential safety risks including brain swelling.

“It is unlikely that the small difference reported in this trial will be noticeable by individual patients,” said Dr Madhav Thambisetty of the National Institute on Aging, who noted he wasn’t speaking for the government agency.

He said many researchers believe a meaningful improvement would require at least a difference of a full point on that 18-point scale.

But Dr Ron Petersen, an Alzheimer’s expert at the Mayo Clinic, said the drug’s effect was “a modest one but I think it’s clinically meaningful” because even a few months’ delay in progression could give someone a little more time when they’re functioning independently.

The trial is important because it shows a drug that attacks a sticky protein called amyloid – considered one of several culprits behind Alzheimer’s – can delay disease progression, said Maria Carrillo, chief science officer for the Alzheimer’s Association.

“We all understand that this is not a cure and we’re all trying to really grasp what it means to slow Alzheimer’s, because this is a first,” Carrillo said.

But any delay in cognitive decline early on could be meaningful for “how much time we have with our loved ones in a stage of disease where we can still enjoy family and outings, vacations, bucket lists,” she said.

Amyloid-targeting drugs can cause side effects that include swelling and bleeding in the brain, and lecanemab did as well. One type of this swelling was seen in about 13 per cent of recipients. Eisai said most were mild or asymptomatic.

Also, two deaths have been publicly reported among lecanemab users who also were taking blood-thinning medications for other health problems. Eisai said the deaths can’t be attributed to the Alzheimer’s drug.

But Mayo’s Petersen said if lecanemab is approved for use in the US, he’d avoid prescribing it to people on blood thinners at least initially.

And Thambisetty said the death reports raise concern about how the drug may be tolerated outside of research studies “where patients are likely to be sicker and have multiple other medical conditions”.

The Food and Drug Administration is considering approving lecanemab under its fast-track programme, with a decision expected in early January. If approved, it would be the second anti-amyloid drug on the market.

Nearly all treatments available for the six million Americans with Alzheimer’s — and millions more worldwide with the most common form of dementia — only temporarily ease symptoms. Scientists don’t yet know exactly how Alzheimer’s forms but one theory is that gunky amyloid build-up plays a key role, although drug after drug that targets it has failed.

In a contentious move last year, the FDA approved the first amyloid-targeting drug, Biogen’s Aduhelm, despite lack of evidence of better patient outcomes. Insurers and many doctors have hesitated to prescribe the pricey drug — another reason experts have anxiously awaited word of how well the newer lecanemab may work.

If the FDA approves lecanemab, patients and their families will need a voice in deciding whether it’s worth the hassle of IV infusions and the risk of side effects for the chance of at least some delay in progression, Petersen said.

“I don’t think we’re going to stop the disease in its tracks” with just amyloid-targeting drugs, he added, saying it will take a combination of medications that target additional Alzheimer’s culprits.

Researchers are preparing to test lecanemab with other experimental drugs, and how it works in high-risk people before they show the first signs of memory problems.

{"website":"website"}{"jamaica-observer":"Jamaica Observer"}
0 Comments · Make a comment

ALSO ON JAMAICA OBSERVER

‘Stop ignoring mining communities’, pleads Russell
Latest News, News
‘Stop ignoring mining communities’, pleads Russell
November 4, 2026
KINGSTON, Jamaica — Member of Parliament (MP) for St Ann South Eastern, Dr Kenneth Russell, is insisting that the time has come for communities in the...
{"jamaica-observer":"Jamaica Observer"}
Headley hits six as Eltham crush Tivoli 9-0 to reach Manning Cup quarters
Latest News, Sports
Headley hits six as Eltham crush Tivoli 9-0 to reach Manning Cup quarters
November 4, 2026
KINGSTON, Jamaica — Captain  Santana Headley scored six times as Eltham High trounced Tivoli Gardens High 9-0 at the Ashenheim Stadium and booked thei...
{"jamaica-observer":"Jamaica Observer"}
Jamaican diaspora urged to support Reggae Boyz v USA South Florida match-up in December
Latest News, Sports
Jamaican diaspora urged to support Reggae Boyz v USA South Florida match-up in December
November 4, 2026
KINGSTON, Jamaica — For the first time since 2011, the Jamaican diaspora in South Florida will have a chance to see the senior Reggae Boyz at home as ...
{"jamaica-observer":"Jamaica Observer"}
Man stabbed to death, brother hospitalised in St Ann sibling dispute
Latest News, News
Man stabbed to death, brother hospitalised in St Ann sibling dispute
November 4, 2026
ST ANN, Jamaica— A man is dead, and his brother admitted to hospital following a domestic dispute in Cascade, St Ann, Wednesday afternoon. The dead ma...
{"jamaica-observer":"Jamaica Observer"}
Latest News, News
WATCH: US midterm results unlikely to shift Holness’ diplomatic approach – Chang
November 4, 2026
KINGSTON, Jamaica – Political commentator Kevin O’Brien Chang does not expect the results of the United States midterm elections, which saw the Democr...
{"jamaica-observer":"Jamaica Observer", "breaking-news":"Push Notifications"}
Adam Hill to lead Proven Properties into next chapter of sustainable growth
Business, Latest News
Adam Hill to lead Proven Properties into next chapter of sustainable growth
November 4, 2026
KINGSTON, Jamaica —  Adam Hill has been appointed chief executive officer of Proven Properties, effective November 1, 2026, the company has announced....
{"jamaica-observer":"Jamaica Observer"}
Soft Power series honours nearly 100 women leaders
Business, Latest News, Lifestyle, ...
Soft Power series honours nearly 100 women leaders
Online feature by Dr Daren Johnson ends with tribute to late Consul General Alsion Roach Wilson
November 4, 2026
An online series that highlighted about 95 women leaders in Jamaica and the diaspora has come to a close, ending with a tribute to the late Consul Gen...
{"jamaica-observer":"Jamaica Observer"}
Gas prices down $2.94, diesel down $.25
Latest News, News
Gas prices down $2.94, diesel down $.25
November 4, 2026
KINGSTON, Jamaica — Motorists should see a decrease at the pumps in the price of gasoline effective Thursday, November 5, according to the latest ex-r...
{"jamaica-observer":"Jamaica Observer"}
❮ ❯

Polls

HOUSE RULES

  1. We welcome reader comments on the top stories of the day. Some comments may be republished on the website or in the newspaper; email addresses will not be published.
  2. Please understand that comments are moderated and it is not always possible to publish all that have been submitted. We will, however, try to publish comments that are representative of all received.
  3. We ask that comments are civil and free of libellous or hateful material. Also please stick to the topic under discussion.
  4. Please do not write in block capitals since this makes your comment hard to read.
  5. Please don't use the comments to advertise. However, our advertising department can be more than accommodating if emailed: advertising@jamaicaobserver.com.
  6. If readers wish to report offensive comments, suggest a correction or share a story then please email: community@jamaicaobserver.com.
  7. Lastly, read our Terms and Conditions and Privacy Policy

Recent Posts

Archives

Facebook
Twitter
Instagram
Tweets

Polls

Recent Posts

Archives

Logo Jamaica Observer
Breaking news from the premier Jamaican newspaper, the Jamaica Observer. Follow Jamaican news online for free and stay informed on what's happening in the Caribbean
Featured Tags
  • Editorial
  • Columns
  • Health
  • Auto
  • Business
  • Letters
  • Page2
  • Football
Categories
  • Business
  • Politics
  • Entertainment
  • Page2
  • Business
  • Politics
  • Entertainment
  • Page2
Ads
img
Jamaica Observer, © All Rights Reserved
  • Home
  • Contact Us
  • RSS Feeds
  • Feedback
  • Privacy Policy
  • Editorial Code of Conduct